← Leaderboards
Valentina Fossati
New York Stem Cell Foundation
$2,050,699
Attributed
$4,671,646
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,671,646 · 2
By mechanism
R01$4,150,732 · 1
R21$520,914 · 1
Top collaborators
- Samuel E Gandy5 shared
- Scott Allen Noggle4 shared
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposS DiseaseMicrogliaPathologyResponse To InjuryRisk VariantNeuronsMouse ModelCoculture TechniquesPathogenesisResponseAstrocytesPhagocytesAutopsyCellsInduced Pluripotent Stem CellCell LineMolecularBrainBrain CellCell TypeClustered Regularly Interspaced Short Palindromic RepeatsProtocols DocumentationS Disease Risk
Grant awards (6)
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2022 · AG · contact PI
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2021 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2020 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2019 · AG
Investigating the biology of human neurotoxic reactive astrocytes using induced pluripotent stem cells$520,914
R21 · FY2019 · NS · contact PI
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$641,748
R01 · FY2018 · AG